ArticleScientific reports2025
Atopic dermatitis-alleviating effects of lactiplantibacillus plantarum LRCC5195 paraprobiotics through microbiome modulation and safety assessment via genomic characterization and in vitro analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Pathway and Mechanism for the Biodegradation of Inosine and Guanosine byFoods (Basel, Switzerland) · 2026Article
- Gram-Positive and Gram-Negative Probiotic Extracellular Vesicles: Mechanisms of Immune Modulation and Therapeutic Opportunities in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
- Antioxidant and Anti-Inflammatory Activities of Probiotic Strains.International journal of molecular sciences · 2026Review
- Engineering Multi-Scale Transdermal Delivery Systems for Atopic Dermatitis: Emerging Insights from the Gut-Skin Axis.International journal of nanomedicine · 2026Review
- Research advances on postbiotics in promoting skin wound healing: mechanisms, formulations, and clinical translation.Frontiers in immunology · 2026Review
- Modulation of Moisturizing and Barrier Related Molecular Markers by Extracellular Vesicles Derived fromCurrent issues in molecular biology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of paraprobiotics from Lactiplantibacillus plantarum LRCC5195 (LP5195-P) in alleviating atopic dermatitis (AD) through microbiome modulation and its safety were evaluated in AD-induced mice. Oral administration of LP5195-P to mice for 8 weeks after AD induction was used to investigate changes in microbiota, immune regulation, and symptoms of dermatitis. Taxonomic analysis of the gut microbiota revealed substantially higher bacterial diversity and abundance in LP5195-P treated group compared to that in negative control. Metabolic analysis revealed significant changes in short-chain fatty acid levels. These microbiome changes correlated with alterations in immune modulation. Furthermore, LP5195-P treatment decreased gene expression related to Treg and Th2 responses in the ileum and skin. Improvements in AD symptoms, including edema and erythema, were observed, and inhibitory effects on histamine release and β-hexosaminidase activity were demonstrated. In conclusion, LP5195-P administration induced a balanced immune response involving gut microbiota and short-chain fatty acids, highlighting its potential as a therapeutic candidate for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.